Posted by Michael Wonder on 29 Mar 2022
Lipocine announces its partner received FDA approval of Tlando
29 March 2022 - Commercial launch expected in 2Q 2022.
Lipocine announced today that Antares Pharma issued a press release announcing that the U.S. FDA has approved Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.
